ReviewFrontiers in chemistry2022
Optical Sensor Array for the Early Diagnosis of Alzheimer's Disease.
Review in Frontiers in chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 20 citations in OpenAlex.
- Developing an integrated dementia care model using service blueprinting: process visualization and failure point analysis.BMC health services research · 2026Article
- The Diagnostic and Therapeutic Potential of Oligonucleotide Aptamers in Alzheimer's Disease.Cells · 2025Review
- Upconversion nanoparticle-FITC conjugate as a fluorescence switching probe for the sensitive detection of Tau: an Alzheimer's disease biomarker.Mikrochimica acta · 2025Article
- Colorimetric sensing for translational applications: from colorants to mechanisms.Chemical Society reviews · 2024Review
- Recent Developments of Hybrid Fluorescence Techniques: Advances in Amyloid Detection Methods.Current protein & peptide science · 2024Review
- DNA-Based Near-Infrared Voltage Sensors.ACS sensors · 2023Article
- Identification of Proteins Using Supramolecular Gold Nanoparticle-Dye Sensor Arrays.Analysis & sensing · 2023Article
- A Multichannel Fluorescent Tongue for Amyloid-International journal of molecular sciences · 2022Article
- Wearable sensors and features for diagnosis of neurodegenerative diseases: A systematic review.Digital healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disorder and has complicated pathobiology, leading to irreversible memory loss and severe cognitive dysfunction. For patients with AD, the advent of the disease usually occurs after years of pathological changes. The early diagnosis and monitoring of AD are of great significance as the early-stage intervention and treatment may be the most effective. Biomarkers, such as beta-amyloid and tau levels in cerebrospinal fluid (CSF) and brain, offer one of the most promising paths and are combined with neuroimaging and immunological detection for AD diagnosis. However, high expense and radiation of neuroimaging and low sensitivity of immunosorbent assay limited their applications. Meanwhile, the relevance of A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.